



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): James H. Aylward

Examiner: C. Tate

**Serial No:** 09/888,178

Art Unit: 1654

Filed: June 21, 2001

For: ANTI-CANCER COMPOUNDS

Dated: January 3, 2003

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

## **RESPONSE**

Sir:

In response to the Restriction Requirement dated December 3, 2003, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, applicant provisionally elects the subject matter of Group I, i.e., Claims 33-89 and 94-99, for continued examination herein.

## **REMARKS**

Claims 33-99 are pending in the above-identified application and have been subjected to a Restriction Requirement under 35 U.S.C. §121 as follows:

> Claims 33-89 and 94-99, drawn to a method of treating cancer using a singular compound, classified in class 514, subclass 100+.

## CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for

Patents, Washington, D.C. 20231 on January 3, 2003.

Dated: January 3, 2003

Mishelle Mustafa